Winter Hematology Update 2023 Conference Report   [Le contenu qui suit est présenté dans sa langue originale : Anglais]   WHU is a content-rich meeting that provides a forum for...

CARE™ Hematology faculty have considered treatment guidance for ALL, CLL, and HL. Faculty involved include:   Drs. Peter Anglin, Isabelle Fleury, Kareem Jamani, John Kuruvilla, Carolyn Owen, and Rob Laister...

The CARE™ at ASH 2022 event was held on December 9th 2022, both virtually and in-person at the NOPSI Hotel in New Orleans, Louisiana. Canadian hematologists contextualized recent international news...

The CARE™ Rheumatology Perspectives report provides a Canadian perspective on relevant clinical trials and news in inflammatory arthritis. Content Foci: Multi disease Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Summary and…

Introduction   CARE™ Hematology Faculty lead, Dr. Peter Anglin, connects virtually with Dr. Versha Banerji to discuss Considerations for treatment rrCLL. const evplayerplyr64821a9f33230 = new Plyr(document.getElementById('plyr64821a9f33230')); evplayerplyr64821a9f33230.ratio = '16:9'; evplayerplyr64821a9f33230.iconUrl...

The 12th annual Canadian Hematology Conference meeting was streamed on Sept. 30th - Oct. 1st 2022. As a follow-up to the meeting, all video components and slide decks are featured in the CHC 2022 virtual...

Introduction   Dr. Alison Moskowitz, Memorial Sloan Kettering Cancer Centre, NY, spoke with CARE™ Hematology Faculty lead, Dr. Peter Anglin, Stronach Regional Cancer Centre, on approaches in frontline advanced Hodgkin...

Introduction Dr. Alison Moskowitz (Memorial Sloan Kettering Cancer Centre, NY) connects virtually with CARE™ Hematology Faculty lead, Dr. Peter Anglin (Stronach Regional Cancer Centre, ON), to discuss treatment of advanced...

Introduction   CARE™ Hematology Faculty lead, Dr. Peter Anglin (Stronach Regional Cancer Centre, ON), connected virtually with international expert Dr. Stephan Stilgenbauer to discuss Considerations for treatment of two separate...

Welcome to Part 2 of the 2022 Forum on Complement Case Discussion Series. PNH is an ultra-rare, and under-recognized complement-mediated disease. Despite its rarity this disease warrants our attention because…